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ABSTRACT
Much of the information on the Cytochrome P450
enzymes (CYPs) is spread across literature and the
internet. Aggregating knowledge about CYPs into
one database makes the search more efficient.
Text mining on 57 CYPs and drugs led to a mass
of papers, which were screened manually for facts
about metabolism, SNPs and their effects on drug
degradation. Information was put into a database,
which enables the user not only to look up a partic-
ular CYP and all metabolized drugs, but also to
check tolerability of drug-cocktails and to find alter-
native combinations, to use metabolic pathways
more efficiently. The SuperCYP database contains
1170 drugs with more than 3800 interactions includ-
ing references. Approximately 2000 SNPs and
mutations are listed and ordered according to their
effect on expression and/or activity. SuperCYP
(http://bioinformatics.charite.de/supercyp) is a
comprehensive resource focused on CYPs and
drug metabolism. Homology-modeled structures of
the CYPs can be downloaded in PDB format and
related drugs are available as MOL-files. Within the
resource, CYPs can be aligned with each other,
drug-cocktails can be ‘mixed’, SNPs, protein point
mutations, and their effects can be viewed and
corresponding PubMed IDs are given. SuperCYP is
meant to be a platform and a starting point for
scientists and health professionals for furthering
their research.
INTRODUCTION
The family of Cytochrome P450 enzymes has been the
focus of pharmaceutical research for decades, as evidenced
by the more than 100000 articles in PubMed. Drug
metabolism is a complex biochemical network, which
consists of many diﬀerent parts and reactions in the
human organism. Some drugs are excreted unchanged in
urine and feces without passing any metabolic treatment
in the liver, but most of the drugs have a multi-step metab-
olism, which is mainly associated with Cytochrome P450
(CYP). These enzymes belong to the family of
monooxygenases, which reach maximum of absorption
at 450nm. This work focuses on human CYPs (Table 1).
The chemical reaction is: R–H+O2+NADPH+
H
+!R–OH+H2O+NADP
+ (1). CYPs catalyze a
large amount of chemical reactions, such as alcohol
oxidations, dehydrogenation and isomerizations. One of
the most diﬃcult tasks of medical science is to ﬁnd
combinations of drugs that do not aﬀect each other’s
metabolic pathways. The Human Genome Project
identiﬁed 57 human CYPs (2), ordered into 18 families
and 43 subfamilies by sequence similarities. In general,
the human CYPs share the same fold, but because of its
spacious binding site CYP 3A4 is capable of metabolizing
at least 422 drugs (Figure 1).
Many drugs also inhibit or induce the activity of CYPs,
which is important to health professionals trying to dose
medicines. If a drug induces a CYP that is also active in
another drug’s metabolism, the dosage of the ﬁrst drug
must be enhanced to achieve a therapeutic eﬀect. In case
of inhibition of a CYP, the dosage of the drug can be
reduced, which also lowers side eﬀects (3). Information
on CYP-structures (4), binding sites (5,6), interactions
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reduce side eﬀects and to determine correct dosages of
medicine. David Nelson and colleagues listed human
CYPs with alignments (9) and also address nomenclature.
Flockhart created a CYP–drug-interaction table with the
intention of avoiding undesired side eﬀects when
prescribing more than one drug (10), a key issue in an
aging society. In 1997, Rendic and Di Carlo (11)
compiled a comprehensive collection of data on CYP
reactions and drug interactions. From the patients’
perspective, it is useful to know what kind of food
or additional drugs they should avoid when taking
their medications. Drug interactions such as these
can be checked at the University of Maryland
Table 1. CYP-overview
CYP Tissue sites Localization Typical reaction
1A1 Lung, several extrahepatic sites, peripher blood cells ER Benzopyrene 3-hydroxylation
1A2 Liver ER Caﬀeine N3-demethylation
1B1 Many extrahepatic sites, incl. lung and kidney ER 17b-Estradiol 4-hydroxylation
2A6 Liver, lung and several extrahepatic sites ER Coumarin 7-hydroxylation
2A7 Only information is identiﬁcation in human genome ER
2A13 Nasal tissue ER Activation of 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone
2B6 Liver, lung ER (S)-Mephenytoin N-demethylation
2C8 Liver ER Taxol 6a-hydroxylation
2C9 Liver ER Tobutamine methyl hydroxylation
2C18 Liver ER
2C19 Liver ER (S)-Mephenytoin 40-hydroxylation
2D6 Liver ER Debrisoquine 4-hydroxylation
2E1 Liver, lung and other tissues ER Chlorzoxazone 6-hydroxylation
2F1 Lung ER 3-Methylindole activation
2J2 Lung ER Arachidonic acid oxidation
2R1 Only information is identiﬁcation in human genome
2S1 Lung ER
2U1 Only information is identiﬁcation in human genome
2W1 Only information is identiﬁcation in human genome
3A4 Liver, small intestine ER Testosterone 6b-hydroxylation
3A5 Liver, lung ER Testosterone 6b-hydroxylation
3A7 Ffetal liver ER Testosterone 6b-hydroxylation
3A43 mRNA detected in gonads ER
4A11 Liver ER Fetty acid x-hydroxylation
4A22 Only information is identiﬁcation in human genome ER
4B1 Lung ER Lauric acid x-hydroxylation
4F2 Liver ER Leukotriene B4 x-hydroxylation
4F3 Neutrophils ER Leukotriene B4 x-hydroxylation
4F8 Seminal vesicles ER Prostaglandin x-2 hydroxylation
4F11 Liver ER
4F12 Liver ER Arachidonic acid x-,x-2-hydroxylation
4F22 Only information is identiﬁcation in human genome
4V2 Only information is identiﬁcation in human genome
4X1 Only information is identiﬁcation in human genome
4Z1 Only information is identiﬁcation in human genome CYP 4A20
5A1 Platelets ER Thromboxane A2 synthetase reaction
7A1 Liver ER Cholesterol 7a-hydroxylation
7B1 Brain ER Dehydroepiandrosterone 7a-hydroxylation
8A1 Aorta, others ER Prostacyclin synthase reaction
8B1 Liver ER 7a-hydroxyprogesterone 12-hydroxylation
11A1 Adrenals, other steroidogenic tissues Mitochondrium Cholesterol side-chain clevage
11B1 Adrenals Mitochondrium 11-Deoxycortisol 11-hydroxylation
11B2 Adrenals Mitochondrium Corticosterone 18-hydroxylation
17A1 Steroidogenic tissue ER Steroid 17a-hydroxylation
19A1 Steroidogenic tissue, adipose, brain ER Androgen aromatization
20A1 Only information is identiﬁcation in human genome
21A2 Steroidogenic tissue ER 17-Hydroxyprogesterone 21-hydroxylation
24A1 Kidney Mitochondrium 25-Hydroxyvitamin D3 24-hydroxylation
26A1 Several ER Retinoic acid 4-hydroxylation
26B1 Brain ER Retinoic acid 4-hydroxylation
26C1 Only information is identiﬁcation in human genome ER
27A1 Liver Mitochondrium Sterol 27-hydroxylation
27B1 Kidney Mitochondrium Vitamin D3 1-hydroxylation
27C1 Only information is identiﬁcation in human genome
39A1 Liver ER 24-Hydroxycholesterol 7-hydroxylase
46A1 Brain ER Cholesterol 24-hydroxylation
51A1 Liver, testes ER Lanosterol 14a-demethylation
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ﬁeld of interest is the diversity of human CYPs in diﬀerent
ethnic groups. Pharmacogenomic studies reported that
African–American patients are precribed higher dosages
of antipsychotic medications compared to Caucasians
(12). Information on mutations in CYPs is widely
spanned accross the internet. An up-to-date resource on
available 3D CYP structures from the Protein Data Bank
(13) is presented by CYPED (14). The Center for
Molecular Design collected exhaustive information on
the CYPs of many species in their Knowledgebase
(http://cpd.ibmh.msk.su/), including sequences and links
to the Nomenclature Committee (15). Despite the large
amount of information on CYPs, optimizing multiple
drug prescriptions using CYP metabolism is still compli-
cated (16). To overcome these problems, SuperCYP aims
at providing a user-friendly platform enabling health
professionals to optimize drug cocktails regarding the
degree of CYP capacity utilization. Furthermore, a
number of scientiﬁc issues were addressed: comprehensive
information about mutations inﬂuencing the metabolism
of drugs (17,18), racial diﬀerences (19), comparative
analysis of drug binding sites to explain their promis-
cuousness. To this end, multiple sequence alignments are
required and will be the basis of homology-built 3D
structures of all human CYPs (20,21).
MATERIALS AND METHODS
Information on CYPs was collected from scientiﬁc litera-
ture (22) and various web resources: e.g. Nelsons
Homepage (23), Flockharts Interaction Table (http://www
.medicine.iupui.edu/Flockhart/table.htm), University of
Maryland’s Drug Checker, PubChem (24), PDB (13).
Some information was gathered from FDA-ﬁles.
Abstracts of PubMed were automatically ﬁltered for
relevant articles using speciﬁc keywords. The abstracts
were screened for WHO-drugs and their synonyms, as
was a set of human CYPs with synonyms. A team of
scientists manually processed the papers found in
PubMed. Each drug was attributed to those CYPs that
are involved in drug metabolism as substrate, inhibitor
or inducer. In addition, mutations on the protein level
were retrieved utilizing the mutation/gene association
text mining system described by Winneburg and
Schroeder (25). The tool retrieved  550 distinct mutations
from more than 400 scientiﬁc journal abstracts. In total,
450 new amino acid substitutions were retrieved in
addition to those 500 already obtained from PubMed.
The approach was adapted to gather information on
alleles, the change of enzyme/transcription activity and
populations. As with the ﬁrst literature screening, the
automated predictions were manually veriﬁed before
being included in the database, and in all cases PubMed-
IDs as references are provided to track details regarding
the given information.
SuperCYP is designed as a relational database on a
MySQL server. For chemical functionality, the MyChem
package is included, which aims to provide a complete set
of functions for handling chemical data within MySQL.
Most of the functions used by MyChem depend on Open
Babel (26). For displaying 3D structures, Jmol—an open-
source Java viewer for chemical structures in 3D—is used.
For visual inspection of the alignments, JALVIEW is
installed. ChemSketch was applied as a built-in molecule
editor, which allows users to screen using self-edited
molecules. The website is built with PHP and javascript,
web access is enabled via Apache Webserver 2.2.
DATABASE
The SuperCYP website was developed as a user-friendly
platform for researchers and health professionals. The
navigation bar on the left side oﬀers ‘FAQs’ or
Frequently Asked Questions, for ﬁrst-time users.
‘Drug search’ enables the user to search for a drug and
ﬁnd information on its metabolism. ‘Get Information’
leads to a table listing CYPs involved in the metabolism
of the drug. Here there is also a description of possible
consequences and after clicking on the drug name on the
results page ‘Drug search’ enables the user to get informa-
tionforcompoundsbymeansoftheCAS-numberorname.
The ‘ATC tree’ is the WHO classiﬁcation system that
classiﬁes drugs into diﬀerent groups according to
anatomic site of action, their therapeutical eﬀect and
chemical structure. It is the basis for drug alternative
drug recommendations. In a Java applet, the user ﬁnds a
drop-down tree with major and minor branches of classi-
ﬁcation. All drugs aﬃliated with a minor branch are listed
in a table and information on the CYP metabolism is
provided.
‘Drug–drug interaction’ is the main feature of the
database. It allows users to enter names of several diﬀerent
drugs and to check interactions between these drugs, but
they also receive alternative drug options.
As an example, Omeprazol, a proton pump inhibitor,
and Nebivolol, a beta-blocker, interact on the CYP level.
After selecting the drugs, the database provides detailed
Figure 1. Plot of the 3D structure of CYP 3A4. Helices are shown as
cylinders (light blue) and beta-sheets as orange arrows. The heme
moiety is depicted in stick representation. The majority of the structure
is made up of an alpha-helical arrangement, but N- and C-terminal
small beta-domains can be found.
Nucleic Acids Research, 2010,Vol.38, Database issue D239information on drug structures and ATC group plus CAS
numbers (Figure 2).
The successive ‘results’ page warns that Omeprazol has
an inhibitory eﬀect on CYP 2D6, whereas Nebivolol is
a substrate. The colored background of the table
illustrates this dual use of the CYP metabolism pathway.
To avoid this and to optimize the drug composition,
Omeprazol can be substituted with other drugs from the
Figure 2. Queries and results of the SuperCyp web-interface explaining the various possibilities of the ‘Drug–drug-interaction’ option with the help
of two example drugs: Omeprazole and Nebivolol.
D240 Nucleic AcidsResearch, 2010, Vol.38,Database issuesame ATC-group, for example Pantoprazol, achieving a
comparable eﬀect, but using another pathway.
The proposal of Pantoprazol is derived from the
assumption that it does not interact with CYP 2D6.
All data on the proposed drugs are provided, and the
reference to related publications is given.
The ‘CYP–Drug-interaction’ allows users to browse
substrates, inducers and inhibitors of a certain CYP
(Figure 3).
After the user has selected a CYP from the task menu,
all known relations with drugs are listed in a table. Then
users can specify the relation and focus on substrates,
inducers or inhibitors. Respective drugs are given in
a table and combined with further information on the
particular drug and all CYP interactions. References are
linked to PubMed and other scientiﬁc websites or articles.
The ‘Drug Info’ button is linked to the SuperDrug
Database (27), which provides a large number of more
speciﬁc information on the particular drug.
‘Polymorphism’ shows single nucleotide polymorphisms
for a particular CYP. All known alleles (15,28) are shown
and if there is a decrease or increase in activity or expres-
sion, this information is provided. Nucleotide changes and
their eﬀects, as well as enzyme activity and assay type are
given with corresponding references. Some mutation
entries address the protein level directly, in which cases
information on SNPs may be missing. However, it is
desirable to include protein data, as they provide
valuable insights into structure-function relationships.
Example: For CYP11B2, which encodes the enzyme
aldosterone synthase (P450aldo), no SNPs were retrieved
through keyword searches. However, our mutation/gene
association text mining system found 54 protein mutations
in 41 PubMed abstracts, which were then added to the
database. Among those, the substitution of the highly
conserved arginine at position 384 by proline reportedly
led to a complete loss of function of this enzyme as part of
the autosomal recessively inherited disorder CMO-I deﬁ-
ciency in male Caucasians.
‘Alignments’ uses a structure-based alignment program
to match the amino acid sequence of all CYPs. It is
possible to create a multiple sequence alignment from
any number of sequences or to align them with external
sequences by uploading a ﬁle or entering a sequence in
FASTA format. Users may also draft a convenient
output with Jalview.
‘Three-dimensional structures’ displays protein struc-
tures of human CYPs. Existing structures were extracted
from the PDB. Theoretical models were generated with
Swiss-Model (29) or built manually. All structures are
downloadable as PDB-ﬁles and more information on the
CYP is given in the box on the right side.
Clicking the ‘Browse’-button leads to a Java applet,
where all CYPs are listed in a drop-down tree, ordered
Figure 3. Results of the SuperCyp web-interface for CYP 2D6 explaining the functionality of the ‘CYP–drug interaction’ table.
Nucleic Acids Research, 2010,Vol.38, Database issue D241by main families and subfamilies. Each CYP is viewable
as a model and further information on its interactions is
provided.
RESULTS
Comprehensive data on the 57 human CYPs are stored
in the SuperCYP database. For all CYPs, the sequences
can be viewed and aligned. Around 1000 SNPs and more
than 1200 protein mutations are listed and ordered by
their eﬀect on expression and/or activity.
The Protein Data Bank (13,30) provides several crystal
structures of Cytochome P450 enzymes. Table 2 lists those
nine CYPs that are represented in PDB, while families 4,
5, 7, 11, 17, 19, 20, 21, 24, 26, 27, 39, 46 and 51 are not.
Based on the known structures, the SuperCYP database
provides theoretical 3D models of the 48 missing human
CYPs (Table 2).
With 1170 drugs and  3800 interactions, SuperCYP
provides the largest number of CYP relations and corre-
sponding information available online. Additionally,
checking the tolerability of drug-cocktails and ﬁnding
alternative uses of metabolic pathways has been made
more eﬃcient with the database.
DISCUSSION
The degradation of compounds by CYPs plays an impor-
tant role in drug–drug interactions that are responsible
for harmful adverse eﬀects, e.g. deadly acute renal
failure (31). Detailed knowledge about CYP–drug
relations is therefore essential for recognizing incompati-
ble drug combinations and to allow individualized
therapies. Besides all-inclusive information about drugs,
CYPs and their relations, descriptive data such as
known CYP-mutations, their phenotypic eﬀects, or the
structural information about the CYPs and drugs will
enable systematic approaches to quantitative structure–
activity relationships. SuperCYP indicates potentially
perilous drug–drug interactions and proposes alternative
drugs improving mixture or dosage. In conclusion, the
server provides a comprehensive resource on CYPs as
well as a discovery tool for analysis of drug degradation
and drug-cocktail optimization.
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SuperCYP is available at http://bioinformatics.charite
.de/supercyp and can be obtained via a Creative
Commons Attribution-Noncommercial-Share Alike 3.0
License. To access all features of the website the latest
version of Java should be installed. The database will be
updated every 6 months.
ACKNOWLEDGEMENTS
We would like to thank Sarah Preissner for her assistance
in completing the structural models of the CYPs.
FUNDING
Deutsche Forschungsgemeinschaft (SFB 449),
Investitionsbank Berlin (IBB), International Research
Training Group (IRTG) Berlin–Boston–Kyoto and
Deutsche Krebshilfe, Bundesministerium fu ¨ r Bildung
und Forschung (BMBF) and European Union (EU).
Funding for open access charge: DFG SFB 449, BMBF.
Conﬂict of interest statement. None declared.
REFERENCES
1. Lepesheva,G.I., Hargrove,T.Y., Kleshchenko,Y., Nes,W.D.,
Villalta,F. and Waterman,M.R. (2008) CYP51: a major drug target
in the Cytochrome P450 superfamily. Lipids, 43, 1117–1125.
2. Ingelman-Sundberg,M. (2005) The human genome project and
novel aspects of cytochrome P450 research. Toxicol. Appl.
Pharmacol., 207, 52–56.
3. Lu,C., Hatsis,P., Berg,C., Lee,F.W. and Balani,S.K. (2008)
Prediction of pharmacokinetic drug-drug interactions using
human hepatocyte suspension in plasma and cytochrome P450
phenotypic data. II. In vitro-in vivo correlation with ketoconazole.
Drug Metab. Dispos., 36, 1255–1260.
4. Keseru,G.M. (1998) Application of theoretical and synthetic models
to cytochrome P450 catalysed metabolic reactions. Acta Pharm.
Hung., 68, 65–69.
5. Fernando,H., Halpert,J.R. and Davydov,D.R. (2006) Resolution of
multiple substrate binding sites in cytochrome P450 3A4: the
stoichiometry of the enzyme-substrate complexes probed by FRET
and Job’s titration. Biochemistry, 45, 4199–4209.
6. Dell,H., Wong,S.C., Phillips,I.R. and Shephard,E.A. (1998)
Identiﬁcation of regulatory protein-binding sites in cytochrome
P450 genes by means of the gel-retardation assay. Methods Mol.
Biol., 107, 381–394.
7. Bertilsson,L. (1995) Geographical/interracial diﬀerences in
polymorphic drug oxidation. Current state of knowledge of
cytochromes P450 (CYP) 2D6 and 2C19. Clin. Pharmacokinet, 29,
192–209.
8. Bathum,L., Andersen-Ranberg,K., Boldsen,J., Brosen,K. and
Jeune,B. (1998) Genotypes for the cytochrome P450 enzymes
CYP2D6 and CYP2C19 in human longevitY. Role of CYP2D6 and
CYP2C19 in longevity. Eur. J. Clin. Pharmacol., 54, 427–430.
9. Nelson,D.R. (2002) Mining databases for cytochrome P450 genes.
Methods Enzymol., 357, 3–15.
10. Flockhart,D.A. and Oesterheld,J.R. (2000) Cytochrome P450-
mediated drug interactions. Child Adolesc. Psychiatr. Clin. N. Am.,
9, 43–76.
11. Rendic,S. and Di Carlo,F.J. (1997) Human cytochrome P450
enzymes: a status report summarizing their reactions, substrates,
inducers, and inhibitors. Drug Metab. Rev., 29, 413–580.
12. Bakare,M.O. (2008) Eﬀective therapeutic dosage of antipsychotic
medications in patients with psychotic symptoms: Is there a racial
diﬀerence? BMC Res. Notes, 1, 25.




2A6 1z10, 1z11, 1fdu, 2fdv, 2fdw, 2fdy, 2pg5, 2pg6, 2pg7
2A13 2p85
2C8 1pq2, 2nni, 2vn0
2C9 1og2, 1og5, 1r9o
2D6 2f9q
2R1 3c6g
3A4 1w0e, 1w0f, 1w0g, 1tqn, 2j0d, 2v0m
8A1 2iag
D242 Nucleic AcidsResearch, 2010, Vol.38,Database issue13. Berman,H.M., Westbrook,J., Feng,Z., Gilliland,G., Bhat,T.N.,
Weissig,H., Shindyalov,I.N. and Bourne,P.E. (2000) The Protein
Data Bank. Nucleic Acids Res., 28, 235–242.
14. Fischer,M., Knoll,M., Sirim,D., Wagner,F., Funke,S. and Pleiss,J.
(2007) The Cytochrome P450 Engineering Database: a navigation
and prediction tool for the cytochrome P450 protein family.
Bioinformatics, 23, 2015–2017.
15. Sim,S.C. and Ingelman-Sundberg,M. (2006) The human
cytochrome P450 Allele Nomenclature Committee Web site:
submission criteria, procedures, and objectives. Methods Mol. Biol.,
320, 183–191.
16. Radhakrishnan,M.L. and Tidor,B. (2008) Optimal drug cocktail
design: methods for targeting molecular ensembles and insights
from theoretical model systems. J. Chem. Inf. Model, 48,
1055–1073.
17. van der Weide,J. and Steijns,L.S. (1999) Cytochrome P450 enzyme
system: genetic polymorphisms and impact on clinical
pharmacology. Ann. Clin. Biochem., 36(Pt 6), 722–729.
18. Giacomini,K.M., Brett,C.M., Altman,R.B., Benowitz,N.L.,
Dolan,M.E., Flockhart,D.A., Johnson,J.A., Hayes,D.F., Klein,T.,
Krauss,R.M. et al. (2007) The pharmacogenetics research network:
from SNP discovery to clinical drug response. Clin. Pharmacol.
Ther., 81, 328–345.
19. Jaja,C., Burke,W., Thummel,K., Edwards,K. and Veenstra,D.L.
(2008) Cytochrome p450 enzyme polymorphism frequency in
indigenous and native American populations: a systematic review.
Community Genet., 11, 141–149.
20. Lewis,D.F., Ito,Y. and Goldfarb,P.S. (2006) Structural modelling of
the human drug-metabolizing cytochromes P450. Curr. Med.
Chem., 13, 2645–2652.
21. Michalsky,E., Goede,A. and Preissner,R. (2003) Loops In Proteins
(LIP)—a comprehensive loop database for homology modelling.
Protein Eng., 16, 979–985.
22. Montellano,P.R.O.d. (2004) Cytochrome P450: Structure,
Mechanism, and Biochemistry, 3rd edn. Springer, Netherlands.
23. Nelson,D.R. (2006) Cytochrome P450 nomenclature, 2004.
Methods Mol. Biol., 320, 1–10.
24. Geer,L.Y., Marchler-Bauer,A., Geer,R.C., Han,L., He,J., He,S.,
Liu,C., Shi,W. and Bryant,S.H. (2009) The NCBI BioSystems
database. Nucleic Acids Res.
25. Winnenburg,R., Plake,C. and Schroeder,M. (2008) Mutation
tagging with gene identiﬁers applied to membrane protein stability
prediction. Proceedings of the ECCB 2008 Workshop: Annotation,
Interpretation and Management of Mutations (AIMM).
26. Guha,R., Howard,M.T., Hutchison,G.R., Murray-Rust,P.,
Rzepa,H., Steinbeck,C., Wegner,J. and Willighagen,E.L. (2006) The
Blue Obelisk-interoperability in chemical informatics. J. Chem. Inf.
Model, 46, 991–998.
27. Goede,A., Dunkel,M., Mester,N., Frommel,C. and Preissner,R.
(2005) SuperDrug: a conformational drug database. Bioinformatics,
21, 1751–1753.
28. Lee,S.J., Perera,L., Coulter,S.J., Mohrenweiser,H.W., Jetten,A. and
Goldstein,J.A. (2007) The discovery of new coding alleles of
human CYP26A1 that are potentially defective in the metabolism
of all-trans retinoic acid and their assessment in a recombinant
cDNA expression system. Pharmacogenet. Genomics, 17, 169–180.
29. Arnold,K., Bordoli,L., Kopp,J. and Schwede,T. (2006)
The SWISS-MODEL workspace: a web-based environment
for protein structure homology modelling. Bioinformatics, 22,
195–201.
30. Sussman,J.L., Lin,D., Jiang,J., Manning,N.O., Prilusky,J., Ritter,O.
and Abola,E.E. (1998) Protein Data Bank (PDB): database of
three-dimensional structural information of biological
macromolecules. Acta Crystallogr. D Biol. Crystallogr., 54,
1078–1084.
31. Kusus,M., Stapleton,D.D., Lertora,J.J., Simon,E.E. and
Dreisbach,A.W. (2000) Rhabdomyolysis and acute renal failure in
a cardiac transplant recipient due to multiple drug interactions.
Am. J. Med. Sci., 320, 394–397.
Nucleic Acids Research, 2010,Vol.38, Database issue D243